An open up-label examine was completed in 2016 in the UK to research the feasibility, safety and efficacy of psilocybin in managing individuals with unipolar treatment-resistant depression with promising outcomes; although the analyze was small and concerned only twelve people, seven of Those people sufferers achieved official criteria for remissio